{"success":true,"data":{"pressRelease":{"id":"160789","rtpr_id":"nGNX6TslDS-20261005","ticker":"AARD","exchange":"NASDAQ","all_tickers":["AARD"],"title":"AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law ","author":"Globe Newswire","published_at":"2026-10-05T14:35:37.100Z","article_body":"LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=e2AktHjDRfTmkXqXEXx-vGc4K5wt7l8YnNKdLTCLOQ77QfHpO-js4AqxiCANp2nhZg_uJuViq1_E7DO18XirU8TjWPcZ5fDMpALuKV2T07skboz7flmap_H-C1Xzcmq2)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark”\nor “the Company”) (NASDAQ: AARD\n(https://www.globenewswire.com/Tracker?data=bLW9wCwbk8RBv_xXqFc0fPXXMHmLZ3NEhkj8mUnz0tSL29IVJ7Lx_baGFVSosAIqKtTXTOU8lkLkLJTGXrMRZwj48IpTaq2O4RX5e5SbiiI=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of AARD during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: Pursuant and/or traceable to the Company's February 13, 2025,\ninitial public offering (\"IPO\") and/or from February 13, 2025 to May 14, 2026.\n\nDEADLINE: October 13, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=b3J0ZIeuodJ-eNrx3JxidnxSXjYc-pGA3DFTN8Buk7huWJL58gEZQcqQHwU3W2gOf3QSF9bZ-2li-NwG3oVSaC3m56l_pll7NXALj_Gx7crhvU4868uGB3_Ulsb7_cY7KKYQuJtVtneuX6w9tMqUrw==).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Aardvark misled investors about the\nsafety profile of its ARD-101 drug candidate. The Company overstated\nARD-101’s clinical and commercial prospects. Based on these facts, the\nCompany’s public statements were false and materially misleading throughout\nthe IPO period. When the market learned the truth about Aardvark, investors\nsuffered damages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=FCStORznxlVzsSM7CAcu_9Q7KqDbloyCXCm441BOfu-QHhticKVGmDUr9DsAXMgWqDU5vZPJMnVmSKPJiWsNAHht6yhQecUi6UTOGIngnNHvSf2AARbvFjSwqYwHAmsJiov9Od1FvGUz9rIfEOJU5g==)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nSchall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6TslDS-20261005","title":"AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law ","author":"Globe Newswire","ticker":"AARD","created":"2026-10-05T14:35:37.100Z","tickers":["AARD"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=e2AktHjDRfTmkXqXEXx-vGc4K5wt7l8YnNKdLTCLOQ77QfHpO-js4AqxiCANp2nhZg_uJuViq1_E7DO18XirU8TjWPcZ5fDMpALuKV2T07skboz7flmap_H-C1Xzcmq2)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark”\nor “the Company”) (NASDAQ: AARD\n(https://www.globenewswire.com/Tracker?data=bLW9wCwbk8RBv_xXqFc0fPXXMHmLZ3NEhkj8mUnz0tSL29IVJ7Lx_baGFVSosAIqKtTXTOU8lkLkLJTGXrMRZwj48IpTaq2O4RX5e5SbiiI=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of AARD during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: Pursuant and/or traceable to the Company's February 13, 2025,\ninitial public offering (\"IPO\") and/or from February 13, 2025 to May 14, 2026.\n\nDEADLINE: October 13, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=b3J0ZIeuodJ-eNrx3JxidnxSXjYc-pGA3DFTN8Buk7huWJL58gEZQcqQHwU3W2gOf3QSF9bZ-2li-NwG3oVSaC3m56l_pll7NXALj_Gx7crhvU4868uGB3_Ulsb7_cY7KKYQuJtVtneuX6w9tMqUrw==).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Aardvark misled investors about the\nsafety profile of its ARD-101 drug candidate. The Company overstated\nARD-101’s clinical and commercial prospects. Based on these facts, the\nCompany’s public statements were false and materially misleading throughout\nthe IPO period. When the market learned the truth about Aardvark, investors\nsuffered damages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=FCStORznxlVzsSM7CAcu_9Q7KqDbloyCXCm441BOfu-QHhticKVGmDUr9DsAXMgWqDU5vZPJMnVmSKPJiWsNAHht6yhQecUi6UTOGIngnNHvSf2AARbvFjSwqYwHAmsJiov9Od1FvGUz9rIfEOJU5g==)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nSchall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-05T14:35:37.146982855Z","server_sent_at_ms":1791210937146},"received_at":"2026-10-05T14:35:37.198Z","source_url":null},"analysis":{"id":"149343","press_release_id":"160789","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["pending securities fraud class action alleging misleading statements about ARD-101 safety and commercial prospects"],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding AARD investors of a securities class action and a lead plaintiff deadline of October 13, 2026.\n\nThe complaint alleges Aardvark misled investors about the safety profile and clinical and commercial prospects of its ARD-101 drug candidate around the February 13, 2025 IPO, with a class period through May 14, 2026.\n\nThis is law-firm advertising, not an issuer disclosure; the class has not been certified and no settlement is announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"class_period":"February 13, 2025 (IPO) and/or February 13, 2025 to May 14, 2026","lead_plaintiff_deadline":"October 13, 2026"}},"quotedText":"Aardvark misled investors about the safety profile of its ARD-101 drug candidate. The Company overstated ARD-101’s clinical and commercial prospects.","namedEntities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"founding partner, Schall, Brown & Schwartz LLP"}],"products":["ARD-101"],"companies":[{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"target of class action lawsuit"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Schall, Brown & Schwartz LLP reminding investors of an existing class action and soliciting lead plaintiff candidates before the October 13, 2026 deadline. No new issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"AARD"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding AARD investors of a securities class action and a lead plaintiff deadline of October 13, 2026.\n\nThe complaint alleges Aardvark misled investors about the safety profile and clinical and commercial prospects of its ARD-101 drug candidate around the February 13, 2025 IPO, with a class period through May 14, 2026.\n\nThis is law-firm advertising, not an issuer disclosure; the class has not been certified and no settlement is announced.","key_figures":{"customDimensions":{"class_period":"February 13, 2025 (IPO) and/or February 13, 2025 to May 14, 2026","lead_plaintiff_deadline":"October 13, 2026"}},"named_entities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"founding partner, Schall, Brown & Schwartz LLP"}],"products":["ARD-101"],"companies":[{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"target of class action lawsuit"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T14:35:41.992Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4701,"modelName":"glm-5.3-flashx"}}